Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Tiziana Life Sciences ( (TLSA) ) has issued an update.
On September 15, 2025, Tiziana Life Sciences announced that it received a research grant from the U.S. Department of Defense to study the use of its intranasal anti-CD3 therapy for traumatic spinal cord injury (SCI). This grant supports Tiziana’s strategy to expand the therapeutic applications of its platform beyond autoimmune and neuroinflammatory diseases to address large, underserved neurological conditions. The funding will support a three-year study focusing on the acute phase of SCI and a two-year Stepping Strong Breakthrough Award for research into the chronic phase. This initiative represents a significant commercial opportunity, given the high disease burden and lack of approved therapies for SCI.
The most recent analyst rating on (TLSA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Tiziana Life Sciences stock, see the TLSA Stock Forecast page.
More about Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing breakthrough therapies using transformational drug delivery technologies. The company specializes in alternative routes of immunotherapy, with its lead candidate being intranasal foralumab, a fully human anti-CD3 monoclonal antibody. Tiziana’s innovative nasal approach aims to improve efficacy, safety, and tolerability compared to traditional intravenous delivery methods.
Average Trading Volume: 350,866
Technical Sentiment Signal: Buy
Current Market Cap: $188.4M
Find detailed analytics on TLSA stock on TipRanks’ Stock Analysis page.